This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alvarez-Sala, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alvarez-Sala, J.-L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2006, p. 1762-1767, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1762-1767.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Clinical and Bacteriological Efficacy in Treatment of Acute Exacerbations of Chronic Bronchitis with Cefditoren-Pivoxil versus Cefuroxime-Axetil

Jose-Luis Alvarez-Sala,1 Peter Kardos,2 Jesús Martínez-Beltrán,3 Pilar Coronel,4 Lorenzo Aguilar,5* and the Cefditoren AECB Working Group{dagger}

Pneumology Department, Hospital Clinico San Carlos, Madrid, Spain,1 Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, Germany,2 Microbiology Department, Hospital Ramón y Cajal, Madrid, Spain,3 Scientific Department, Tedec-Meiji Farma, Madrid, Spain,4 Microbiology Department, School of Medicine, Universidad Complutense, Madrid, Spain5

Received 26 July 2005/ Returned for modification 3 October 2005/ Accepted 2 March 2006

A randomized, double-blind, double-dummy trial was performed comparing 200 mg of cefditoren-pivoxil twice daily for 5 days versus standard cefuroxime-axetil treatment (250 mg twice daily for 10 days) of Anthonisen type I or II acute exacerbations of chronic bronchitis. The modified intention-to-treat population included 541 patients. Patients were assessed during therapy, at the end of therapy (visit 3; primary evaluation time point), and at follow-up. Clinical success was obtained in 79.9% of the 264 patients included in the cefditoren-pivoxil group and in 82.7% of the 277 patients in the cefuroxime-axetil group (treatment difference, 95% confidence interval [CI]: –2.8, –9.7 to 3.6%). Treatment clinical effects were more clearly seen in sputum signs (decreasing volume and purulence from approximately 80% to approximately 10% of the patients). At the end of treatment, exploratory analysis of the per-pathogen bacteriological response showed 72.8% (of 103 isolates) in the cefditoren-pivoxil arm versus 67.0% (of 94 isolates) in the cefuroxime-axetil group (treatment difference; 95% CI: 5.8, –7.0 to 18.6%). Globally, the per-pathogen bacteriological response correlated well with clinical success: 83.5% of 164 baseline isolates from patients with a clinical success were eradicated or presumably eradicated, in contrast to only 3% of 33 isolates from patients with a clinical failure. Clinical success in patients infected with Haemophilus influenzae, the most frequent isolate, was 84% (of 50) and 82.5% (of 40) (treatment difference; 95% CI: 1.5, –14 to 17%) in the cefditoren-pivoxil versus the cefuroxime-axetil group. Although this study does not prove that either drug is better than a placebo, cefditoren-pivoxil and the standard 10-day cefuroxime-axetil course had similar point estimates of success in acute exacerbations of chronic bronchitis.

* Corresponding author. Mailing address: Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain. Phone: 34-91-3941511. Fax: 34-91-3941511. E-mail: laguilar{at}med.ucm.es.

{dagger} Members of the Cefditoren AECB Working Group are listed in Acknowledgments.

Antimicrobial Agents and Chemotherapy, May 2006, p. 1762-1767, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1762-1767.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Bulitta, J. B., Landersdorfer, C. B., Kinzig, M., Holzgrabe, U., Sorgel, F. (2009). New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics. Antimicrob. Agents Chemother. 53: 3462-3471 [Abstract] [Full Text]  
  • El Moussaoui, R, Roede, B M, Speelman, P, Bresser, P, Prins, J M, Bossuyt, P M M (2008). Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 63: 415-422 [Abstract] [Full Text]  
  • Yamada, M., Watanabe, T., Miyara, T., Baba, N., Saito, J., Takeuchi, Y., Ohsawa, F. (2007). Crystal Structure of Cefditoren Complexed with Streptococcus pneumoniae Penicillin-Binding Protein 2X: Structural Basis for Its High Antimicrobial Activity. Antimicrob. Agents Chemother. 51: 3902-3907 [Abstract] [Full Text]  
  • Fenoll, A., Aguilar, L., Robledo, O., Gimenez, M.-J., Tarrago, D., Granizo, J.-J., Gimeno, M., Coronel, P. (2007). Influence of the {beta}-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. J Antimicrob Chemother 60: 323-327 [Abstract] [Full Text]  
  • Alou, L., Gimenez, M. J., Sevillano, D., Aguilar, L., Gonzalez, N., Echeverria, O., Torrico, M., Coronel, P., Prieto, J. (2007). Are {beta}-lactam breakpoints adequate to define non-susceptibility for all Haemophilus influenzae resistance phenotypes from a pharmacodynamic point of view?. J Antimicrob Chemother 59: 652-657 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»